ClinicalTrials.gg
RecruitingNCT06245122Updated Apr 6, 2026

A Study of CS23546 in Subjects With Advanced Tumors

A Phase 1 interventional study of CS23546 in Advanced Tumors, sponsored by Chipscreen Biosciences, Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-06.

Sponsored by Chipscreen Biosciences, Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2024; still recruiting 2 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
156
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The primary objectives of this study are to characterize the safety and tolerability of CS23546 and to evaluate the pharmacokinetic (PK) characteristics and recommended phase 2 dose (RP2D) of CS23546 in subjects with advanced tumors.

Read the detailed description

This study is a single arm, open phase I trial, consisting of a dose escalation phase (single dose+multiple doses) and a dose expansion phase, accompanied by pharmacokinetic and pharmacokinetic studies. The first visit period (21 days) of single dose and multiple doses during the dose-increasing phase is the DLT observation period.

02

Conditions studied

  • Advanced Tumors
03

In context

Lead sponsor

Chipscreen Biosciences, Ltd. is the lead sponsor of 42 studies on the registry; 11 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Male or female and ≥18 years of age on day of signing .
  2. or cytologically confirmed unresectable advanced recurrent/ solid tumor or lymphoma that is failure or or intolerant of all standard therapy or for which no standard therapy is available.
  3. Individuals are required to provide tumor tissue samples for prospective detection of Programmed cell death 1 ligand 1 () expression and/or Microsatellite instability (MSI) / the DNA mismatch repair (MMR) status. Subjects who cannot be provided during the dose escalation phase will be evaluated by the researchers and sponsors before deciding whether to enroll.
  4. (ECOG) Performance Status of 0 or 1.
  5. Adequate organ function.
  6. ≥12 weeks.
  7. Dose expansion phase: Cohort 1, Subjects with urothelial carcinoma. Cohort 2, Subjects with Extranodal NK/T-cell lymphoma (NKTCL). Cohort 3, Subjects with soft tissue sarcoma. Cohort 4, Subjects with PD-L1 expression positive and/or microsatellite-instability-high (MSI-H) / mismatch-repair-deficient (dMMR) advanced solid tumors or lymphoma

Key Exclusion Criteria:

  1. Received anti-tumor therapy (including but not limited to chemotherapy, targeted therapy, anti angiogenic therapy, immunotherapy, cell therapy, radiotherapy, tumor embolization, etc.) or experimental drugs/devices that have not been approved for marketing within 28 days before the first medication.
  2. History of ≥ Grade 3 immune related Adverse Events (irAEs) or termination of treatment due to irAEs during prior treatment with Programmed death 1 (PD-1) /PD-L1 antibody.
  3. Active diseases present during the screening period and systemic treatment was received within 2 years before the first medication. Individuals who only require hormone replacement therapy (such as thyroxine, insulin, or physiological used for adrenal or pituitary insufficiency) can be enrolled.
  4. Presence of central nervous system and/or meningeal metastasis.
  5. Dose expansion phase: Subjects with solid tumors or lymphoma who have previously received PD-L1 inhibitors and belong to primary resistance.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
156 participants (estimated)

Study arms

  • Experimental
    Dose escalation

    Single ascending dose (SAD): Participants will receive CS23546 once on the first day (D1). Multiple ascending dose (MAD): Participants will receive CS23546 once daily from the 7th day (C1D1).

    Drug: CS23546

  • Experimental
    Dose expansion

    Dose expansion is planned to begin when the recommended Phase 2 dose (RP2D) will be determined.

    Drug: CS23546

Interventions

  • DrugCS23546

    Tablets administered orally.

06

What researchers measure

Primary outcomes

  1. Dose Limiting Toxicities (DLTs)

    DLT: Number of patients experienced any dose limited toxicity. MTD: One level lower than the dose level at which dose escalation was terminated due to DLT reasons.

    Time frame: Day 1 through Day 27

  2. Maximum Tolerated Dose (MTD)

    MTD: One level lower than the dose level at which dose escalation was terminated due to DLT reasons.

    Time frame: Day 1 through Day 27

  3. Time to Cmax (Tmax)

    Time to reach the Cmax for CS23546.

    Time frame: up to Day 1 of cycle 5 (each cycle is 21 days)

  4. Maximum plasma concentration (Cmax)

    Maximum observed plasma concentration for CS23546.

    Time frame: up to Day 1 of cycle 5 (each cycle is 21 days)

  5. Area Under the Curve (AUC)

    Area Under the Plasma Concentration-time Curve From Zero Time to the Last Measurable Point for CS23546.

    Time frame: up to Day 1 of cycle 5 (each cycle is 21 days)

Secondary outcomes

  1. The inhibitory activity of Programmed cell death 1 ligand 1 (PD-L1)

    Time frame: up to Day 1 of cycle 5 (each cycle is 21 days)

  2. Interferon gamma (IFN-γ)

    Plasma concentration for IFN-γ.

    Time frame: up to Day 1 of cycle 5 (each cycle is 21 days)

  3. Free PD-L1

    Plasma concentration for free PD-L1.

    Time frame: up to Day 1 of cycle 5 (each cycle is 21 days)

  4. C-X-C motif chemokine 9 (CXCL9)

    Plasma concentration for CXCL9.

    Time frame: up to Day 1 of cycle 5 (each cycle is 21 days)

  5. C-X-C motif chemokine 10 (CXCL10)

    Plasma concentration for CXCL10.

    Time frame: up to Day 1 of cycle 5 (each cycle is 21 days)

  6. Objective response rate (ORR)

    Efficacy evaluation indicators for research.

    Time frame: Until 28 days after the last dose of the study drug

  7. Disease control rate (DCR)

    Efficacy evaluation indicators for research.

    Time frame: Until 28 days after the last dose of the study drug

  8. Duration of response (DOR)

    Efficacy evaluation indicators for research.

    Time frame: Until 28 days after the last dose of the study drug

  9. Time to progression (TTP)

    Efficacy evaluation indicators for research.

    Time frame: Until 28 days after the last dose of the study drug

  10. time to progressive disease (TTR)

    Efficacy evaluation indicators for research.

    Time frame: Until 28 days after the last dose of the study drug

  11. Progression free survival (PFS)

    Efficacy evaluation indicators for research.

    Time frame: Until 28 days after the last dose of the study drug

  12. Overall survival (OS)

    Efficacy evaluation indicators for research.

    Time frame: Until 28 days after the last dose of the study drug

  13. Safety indicators: adverse events (AE)

    The incidence and severity of adverse events (AE) (according to CTCAE v5.0).

    Time frame: Until 28 days after the last dose of the study drug

07

Study locations

1 of 1 sites recruiting
  • Sun Yat-sen University Cancer Cancer
    Guangzhou, China
    Recruiting
    • Su Li · Contact
    • Huiqiang Huang, Ph.D. · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2024 (actual). Primary completion is estimated for Feb 2027, 35 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 26, 2023
First posted
Feb 7, 2024
StartActual
Mar 27, 2024
Primary completionEst.
Feb 28, 2027
CompletionEst.
May 31, 2027
Last update
Apr 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06245122
Responsible party
Sponsor
First posted
Feb 7, 2024
Start date
Mar 27, 2024
Primary completion
Feb 28, 2027 (estimated)
Completion
May 31, 2027 (estimated)
Last update
Apr 6, 2026

Study contacts

Xinhao Wang
Contact
xinhwang@chipscreen.com
+86 0755-36993550
Huiqiang Huang, Ph.D.
principal investigator · Sun Yat-sen University Cancer Cancer

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion